Several clinical trials are currently underway in the U.S. to investigate AXL selective small molecule inhibitors such as BGB324/R428 in Melanoma (NCT02872259-Phase I & II) and TP-0903 in solid tumors (NCT03572634-Phase I & II). The gene discussed is AXL; the disease is melanoma.